Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies
In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. In the meantime, various preclinical and clinical studies have extensively explored dual-target CAR-T therapies which...
Saved in:
Main Authors: | Chenyun Zhang, Haizhou Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/jimr/5845167 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01) -
Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia
by: Danni Xie, et al.
Published: (2025-01-01) -
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
by: Haiying Qin, et al.
Published: (2021-09-01) -
Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic
by: Caitlin R Hopkins, et al.
Published: (2021-12-01) -
CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
by: Marie José Kersten, et al.
Published: (2025-01-01)